Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 17/20 | 0.55 |
| ▸ | GPR183 | P32249 | 1/20 | 0.55 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.46 |
| ▸ | DPP4 | P27487 | 2/20 | 0.45 |
| ▸ | DPP7 | Q9UHL4 | 2/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10476629 | 0.88 | GPR119 (0.47) | GPR119GPR183LMNAMAPT | |
| SCHEMBL4114736 | 0.87 | GPR119 (0.55) | GPR119GPR183CYP3A4CYP2C19 | |
| SCHEMBL4113153 | 0.87 | GPR119 (0.48) | GPR119GPR183CYP3A4CYP2C19LMNA | |
| SCHEMBL4112505 | 0.86 | GPR119 (0.67) | GPR119CYP3A4CYP2C19 | |
| SCHEMBL4102142 | 0.85 | GPR119 (0.45) | GPR119GPR183LMNAMAPT | |
| SCHEMBL4106232 | 0.85 | GPR119 (0.52) | GPR119DPP4DPP7LMNA | |
| SCHEMBL4214372 | 0.81 | GPR119 (0.60) | GPR119DPP4DPP7 | |
| SCHEMBL4106749 | 0.81 | GPR119 (0.44) | GPR119GPR183CYP3A4CYP2C19LMNA | |
| SCHEMBL4114745 | 0.80 | GPR119 (0.43) | GPR119GPR183LMNAMAPT | |
| SCHEMBL19434296 | 0.79 | GPR119 (0.54) | GPR119GPR183CYP3A4CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2013201-B1 | HETEROCYCLIC GPCR AGONISTS | PROSIDION LTD (GB) | 2012-07-25 | — | — | EP | claimed |
| US-20090221639-A1 | Heterocyclic GPCR Agonists | PROSIDION LIMITED (GB) | 2009-09-03 | — | — | US | claimed |
| US-20090221639-A1 | Heterocyclic GPCR Agonists | PROSIDION LIMITED (GB) | 2009-09-03 | — | — | US | disclosed |
| US-20090221639-A1 | Heterocyclic GPCR Agonists | PROSIDION LIMITED (GB) | 2009-09-03 | — | — | US | disclosed |
| US-20090221639-A1 | Heterocyclic GPCR Agonists | PROSIDION LIMITED (GB) | 2009-09-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090221639-A1 | Heterocyclic GPCR Agonists | GPR119, GCGR, GLP1R | GPR119 1/4885GPR183 32/4885CYP3A4 1701/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.